Novo Nordisk (NVO) Pulls Back Sharply, Is It A Bargain?

Novo Nordisk (NYSE:NVO) has been on many investors’ watchlists after its recent share price pullback. With the stock down over the past month and the past 3 months, attention is shifting toward what the current valuation implies.

Over a longer window, Novo Nordisk’s recent pullback sits on top of already weak performance, with the share price down 19.9% over the past month and 24.8% over 3 months, while the 1 year total shareholder return has fallen 35.3%. This points to fading momentum as investors reassess growth expectations and perceived risks against the current valuation.

Scan beyond Novo Nordisk and identify other healthcare leaders that have also sold off recently but still show solid fundamentals with our hand-picked 31 high quality undervalued stocks.

The share price reset now leaves Novo Nordisk trading well below both analyst targets and one intrinsic value estimate. Does that gap signal mispricing, or is it a fair reflection of the risk investors now see?

Most Popular Narrative: 64% Undervalued

Narrative followers see a wide gap between Novo Nordisk’s last close at $37.32 and a fair value of $102.97, framing the recent pullback as a reset rather than a change in the long term story.

The GLP-1 market is growing at an unprecedented rate, with global sales projected to more than double from 2025 levels to reach $190 billion to $200 billion by 2035, with some forecasts projecting the market to exceed $250 billion by 2030-2034 due to the expansion into new therapeutic areas and rapid adoption of oral treatments.

See why 65 investors see Novo Nordisk as 64% undervalued.

According to MCOInvestors, this thesis leans heavily on GLP-1 demand, a forecast fair value of $102.97, and a discount rate of 5.5%. That implies Novo Nordisk trading at a steep discount to that narrative, with the current share price more than 60% below the estimated worth on this framework.

The narrative also anchors its view on profitability, using a 35% profit margin and a future P/E of 22 to frame what the business could justify if sentiment recovers. While those inputs are assumptions rather than guarantees, they highlight how much of the gap depends on long term GLP-1 adoption and regulatory progress playing out as expected.

Result: Fair Value of $102.97 (UNDERVALUED)

Still, the Novo Nordisk narrative can crack if GLP-1 demand undershoots projections, or if regulators delay or reject key approvals for new indications.

Find out about the key risks to this Novo Nordisk narrative.

Next Steps

Mixed sentiment around Novo Nordisk is clear, with sharp price declines set against a bullish valuation story that hinges on GLP-1 expectations. Act quickly by weighing both sides of the argument and then ground your own decision in the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Novo Nordisk?

If Novo Nordisk has sharpened your focus on valuation and risk, do not stop here. Put that curiosity to work by mapping out fresh opportunities with a few targeted stock lists.

• Target dependable income by scanning companies that aim for sturdy payouts with the 7 dividend fortresses.
• Hunt for quality at a discount and see which businesses combine strong fundamentals with appealing prices through the 31 high quality undervalued stocks.
• Prioritise resilience by focusing on firms with cleaner finances and healthier metrics using the list of solid balance sheet and fundamentals (25 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com